| Project
Overview
The recent introduction of a highly effective vaccine against
human papillomavirus (HPV) exposed the need for population-based
surveillance of HPV-related diseases.
In 2007, the Centers for Disease Control and Prevention (CDC)
funded a collaboration between the California Emerging Infections
Program (CEIP) and the California Department of Public Health
(CDPH) STD Control Branch to develop a comprehensive plan to
conduct surveillance of cervical cancer precursor lesions including
cervical intraepithelial neoplasia (CIN) 2/3 and adenocarcinoma
in situ (AIS).
The pilot phase of this project will be conducted in Alameda
County.
Purpose
• To determine the burden of CIN 2/3 and AIS in Alameda
County and monitor trends in incidence,
• Conduct enhanced surveillance and HPV testing for a
subset of cases, and
• Explore the development of infrastructure for statewide
surveillance to evaluate the impact of the HPV vaccine including
disease surveillance, immunization registry, and behavioral
surveillance.
Human
Subject Protection
To ensure compliance with standards for the protection of human
subjects, this project has received approvals from the Institutional
Review Boards (IRB) of the the California Health and Human Services
Agency and the University of California at Berkeley. The project
will be submitted to any other applicable institutions as necessary.
The California State Committee for the Protection of Human Subjects
approval
and HIPAA waiver for this project.
Relevant
Project Documents
For more detailed information about the project, please download
the following PDF documents:
A printable two-page summary of the project titled “HPV-IMPACT:
Human Papillomavirus Vaccine Impact Monitoring Through Surveillance
of Cervical Precancerous Lesions in California”
How is information requested? See a sample case
report form that may be faxed to providers.
The Centers
for Disease Control and Prevention’s Determination
of Non-Research for this project
 |
January
2012 Update: the California HPV-IMPACT site published a
newsletter to update collaborators on surveillance project
activities and news about HPV and the HPV vaccine. Read
or download a PDF of the newsletter. |
National
Collaborating Surveillance Sites and Participating Institutions
Connecticut Emerging Infections Program, Yale University
Tennessee Department of Health, Tennessee Emerging Infections
Program, Vanderbilt University
New York Emerging Infections Program, University of Rochester
Oregon Emerging Infections Program, State of Oregon Department
of Human Services
Kaiser Permanente of Northern California
Questions
about the Project?
If you have any questions about the project, please contact
either
Ina
Park, MD MS
Chief, Office of Medical and Scientific Affairs
STD Control Branch
California Department of Public Health
850 Marina Bay Parkway, Bldg P, 2nd Floor
Richmond, CA 94804
ina.park@cdph.ca.gov
(510) 620-6287 |
Erin
Whitney, MPH
HPV Surveillance Project Coordinator
STD Control Branch
California Department of Public Health
850 Marina Bay Parkway, Bldg P 2nd Floor
Richmond, CA 94804
erin.whitney@cdph.ca.gov
(510) 620-2379 |
Links
For more information on HPV and the HPV vaccine:
The
Centers for Disease Control and Prevention HPV Page
The California
Department of Public Health HPV Vaccine Workgroup
The
California Department of Public Health Human Papillomavirus
(HPV) Page
Report
on Cervical Cancer in California, 2008 by the California Cancer
Registry (PDF)
Return
to top of page
|
